The effects of ETN/CZP treatment in the mixed cohort of RA + AS, as well as in RA and AS patients, on disease activity (DAS28-CRP) and CRP levels, have been published earlier [9,19]. The gene discussed is CRP; the disease is rheumatoid arthritis.